CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough Summit
BioMarin, Jazz Pharmaceuticals, and Otsuka CEOs to Join NORD CEO to Examine What it Takes to Turn Scientific Advancements into Patient Progress WASHINGTON, Oct. 6, 2026 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) today announced that CNBC "Squawk Box" co-anchor...
Covered in this story
Call it yourself
No calls on $JAZZ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Jazz Pharmaceuticals →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.